Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2021 01:30 ET | Source: AB2 Bio

AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Investors can pre-register for the event here LAUSANNE, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the...
December 16, 2020 01:30 ET | Source: AB2 Bio

AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer

Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3Joins AB2 Bio from Novartis and has extensive commercial and strategic experience LAUSANNE, Switzerland, Dec. 16,...
October 29, 2020 06:00 ET | Source: AB2 Bio

AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH)WuXi Biologics to undertake commercial...
March 03, 2020 01:00 ET | Source: AB2 Bio

AB2 Bio Appoints Michael Soldan CEO

LAUSANNE, Switzerland, March 03, 2020 (GLOBE NEWSWIRE) -- AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company specialized in developing innovative therapies for the treatment of severe...